3 Giralda Farms, Madison, NJ USA
Public NYSE: DGX
Quest Diagnostics is a U.S., Fortune 500 company that performs diagnostic tests "on about 150 million specimens each year, including routine tests such as cholesterol checks, Pap smears, HIV screenings, and drug tests. Quest Diagnostics also performs esoteric testing (such as genetic screening) and anatomic pathology testing (such as tissue biopsies for cancer testing). The company directly serves doctors and hospitals, as well as corporations, government agencies, and other clinical labs. It has more than 2,000 patient service centers where samples are collected, along with about 30 primary labs and 150 rapid response labs throughout the US, as well as internationally."
 Worker Rights
- CEO Surya Mohapatra had total pay of $11,322,335 in 2008 according to the AFL-CIO Executive PayWatch Database. In 2007 he made about the same, $11,469,668.
- Quest Pays $688,772 in Back Wages for Violating Federal Labor Laws, April 28, 2008. The U.S. Department of Labor brought a lawsuit against medical laboratory operator Quest Diagnostics Inc., a company that collects blood, urine and tissue samples from medical centers for medical diagnosis, saying that it failed to adequately pay its employees, misclassifying them as being exempt from overtime requirements. The suit stated that the company had failed to fully pay 238 employees nationwide. Following complaints, the federal agency investigated records at Quest's Cambridge lab. The investigations revealed that client systems analysts nationwide didn't receive overtime pay they deserved. As part of a settlement reached in the case, Madison, NJ, based Quest agreed to pay $688,772 in back wages for alleged violations of federal labor law.
 Political Influence
- In the 2008 U.S. election, Quest Diagnostics gave $82,250 to Federal candidates through its political action committee - 69% to Democrats and 31% to Republicans.
- In 2006, it gave $82,750 - 45% to Democrats and 55% to Republicans.
- In 2009, it spent $700,000 for lobbying to attain legislation that the company desired.
 Business Ethics
Quest Diagnostics has reached a $302 million settlement which will resolve criminal and civil allegations regarding some of its diagnostic test kits manufactured and sold up to 2006.
The federal investigation was initiated based on branding and false claims allegations made by a whistleblower, who subsequently received nearly $45 million as settlement of the whistleblower lawsuit. It was one of the largest recoveries in a medical devices case.
The terms of the $302 million settlement by Quest Diagnostics and its Nichols Institute Diagnostics (NID) unit are that the 2 entities will pay $262 million plus interest to resolve federal False Claims Act allegations pertaining to diagnostic tests manufactured by NID that allegedly provided inaccurate and unreliable results.
Additionally, NID will pay a $40 million fine having now pled guilty to felony misbranding regarding its test used to measure parathyroid hormone levels.
 Human Rights
- Quest Diagnostics received a good score (85 out of 100) from the Human Rights Campaign which puts out a buying guide that rates corporations on policies that affect gays and lesbians.http://www.hrc.org/buyersguide
 Brands and Subsidiaries
- American Medical Laboratories, DPD Holdings, Enterix, Focus GmbH, Focus Technologies, HemoCue, QDI Acquisition AB (Sweden), Lab Portal, LabOne, Lifepoint Medical Corporation, MedPlus, Unilab Corporation, Nichols Institute Diagnostics, Nomad Massachusetts, OralDNA Labs, AmeriPath Group Holdings